The Biostatistics Core will provide biostatistical expertise in the design, conduct and analysis of the clinical trials, animal studies and related research projects generated under this proposal. The goals of the Core are to provide biostatistical support to the six projects at all stages of the research. Prior to the initiation of studies, Core staff will consult with investigators to review study objectives and assist in selecting efficient designs and sample sizes that will provide adequate power to address study objectives. For clinical studies, a Core member will conduct a protocol review with investigators and assist in protocol development, sample size determination, plans for interim analyses and if applicable, randomization. Core staff will perform statistical analyses and data exploration for P01 investigators using appropriate statistical methodologies; prepare reports of results; assist investigators with the preparation of presentations and writing of statistical components of manuscripts; and consult on the design of subsequent research. The biostatistical team also has widespread experience in applied and methodologic statistical research, which will allow for the most appropriate methodologies to be utilized as well as to modify or develop new methods if needed.

Public Health Relevance

The Biostatistics Core is essential to the design, ongoing review and final analysis of preclinical experiments and clinical trials to translate biological questions into experimentally testable hypotheses yielding interpretable results and to insure that planned clinical trials are feasible, invoke appropriate design and stopping rules to insure safety and are appropriately analyzed and interpreted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023766-40
Application #
9984301
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
40
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Haak, Bastiaan W; Littmann, Eric R; Chaubard, Jean-Luc et al. (2018) Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT. Blood 131:2978-2986
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824

Showing the most recent 10 out of 452 publications